Zynerba updates on its two clinical CBD studies
Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with Proactive Investors at the BIO CEO & Investor Conference in New York.
Anido says the company is on track to report results from CONNECT-FX, its clinical study of CBD in children and adolescents with Fragile X Syndrome in the second half of 2019. It has completed enrollment in its Phase 2 BELIEVE 1 of ZYN002 to treat epileptic encephalopathy, with top-line results will be reported in the third quarter of 2019.